Skip to main content

Table 2 Comparison of median doses (interquartile range) in the six months prior to and six months after inflammatory disease therapy initiation

From: Claims for disease-modifying therapy by Alberta non-insured health benefits clients

  Acetaminophen NSAIDsa Opioidsb Corticosteroidsc
DMARDs Only (Incident to database after 2002)
n = 456
Pre: 180.6 mg
(88.9–500)
Post: 277.8 mg (88.9–666.7)
(p = 0.7)
Pre: 455.6 mg (216.7–866.7)
Post: 547.9 mg (233.3–1067.7)
(p = 0.02)
Pre: 3.3 mg
(1.1–9.4)
Post: 3.4 mg
(0.8–14.0)
(p = 0.08)
Pre: 6.2 mg
(1.8–11.4)
Post: 5.3 mg
(2.1–13.7)
(p = 0.7)
Biologic Usersd
n = 229
Pre: 277.8 mg (166.7–833.3)
Post: 277.8 mg (83.3–555.6)
(p = 0.5)
Pre: 600.0 mg (305.3–1200.0)
Post: 633.3 mg (300.0–1333.3)
(p = 0.2)
Pre: 18.0 mg
(5.0–56.1)
Post: 22.3 mg
(7.4–58.4)
(p = 0.04)
Pre: 5.0 mg
(1.75–10.0)
Post: 5.8 mg
(2.1–10.6)
(p = 0.02)
  1. amg of ibuprofen equivalent
  2. bmg of morphine equivalent
  3. cmg of prednisone equivalent
  4. dIncludes patients with data available for 6 months prior to and following biologic initiation